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CD107aAntibody-dependent cellular cytotoxicity (ADCC) may assist in preventing HIV or delaying disease
progression. Most prior studies have analysed Env-speciﬁc ADCC responses. We hypothesized that effective
ADCC-based immunity may target conserved internal viral proteins such as Pol. We analysed the ability
overlapping Pol peptides to induce activation of NK cells via ADCC. We prospectively studied ADCC responses
in 83 HIV+ subjects followed for 3 years. Pol peptides were commonly targeted by ADCC responses in these
chronically infected subjects (in 32 of the 83 subjects). However, Pol-speciﬁc ADCC responses declined over
time and did not correlate with delayed HIV progression, measured by either baseline CD4 T cells, CD4 T cell
loss over time, baseline viral load or the need to start antiretroviral therapy. Although Pol is frequently
targeted by ADCC in HIV+ subjects, the strength or speciﬁcity of Pol-speciﬁc ADCC responses needs to be
modulated to be effective in delaying HIV progression.l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) is an important
global pandemic with close to 3 million new infections each year. An
HIV vaccine is urgently needed. Protein subunit vaccines induce only
narrowly directed neutralizing antibodies, and failed to protect in
human and macaque trials (Pitisuttithum et al., 2006; Stott, 1991).
Vaccination with recombinant adenoviruses expressing HIV proteins
elicited HIV-speciﬁc CD8+ T lymphocytes (McElrath et al., 2008), but
also do not protect against infection or reduce viral load set point in
those individuals who became infected during follow-up (Buchbinder
et al., 2008). These disappointing results after years of HIV vaccine
research suggests newer concepts in immunity to HIV should be
explored (Isitman et al., 2009). Importantly, a recent efﬁcacy trial
based on a recombinant Canarypox virus prime and envelope protein
boost showed partial protection from infection, despite only inducing
narrowNab responses andminimal CTL responses. High levels of non-
neutralizing antibodies were induced by this regime, suggesting such
responses could play a role in protective immunity (Rerks-Ngarm et
al., 2009).
ADCC is an immune response combining components of innate
and humoral immunity. Cells that can be activated by ADCC to provideeffector functions via their Fc receptors include NK (Natural Killer)
cells, neutrophils and macrophages. ADCC utilizes effector cells
bearing Fc gamma (FcγR) or CD16 receptors such as NK cells attracted
by antibodies of the IgG isotype to the target antigens on the surface of
virus-infected cells. NK cells comprise 15% of the peripheral blood
lymphocytes. Lysis of virus-infected cells occurs once the ADCC
antibodies bind to surface viral antigens and interact with the FcγR of
NK cells. The activation of NK cells elicits release of perforin,
granzymes and cytokines including IFNγ, IL-1, TNFα and GM-CSF. A
series of in vitro studies have demonstrated the presence of ADCC
antibodies against HIV in the plasma of the majority of subjects
infected with HIV-1 (Forthal et al., 2001; Ljunggren et al., 1990). HIV-
speciﬁc ADCC responses generally correlate with delayed HIV
progression (Baum et al., 1996). Importantly, Hessel and colleagues
showed signiﬁcant decreases in the efﬁcacy of mutated neutralizing
antibodies that were no longer able to elicit ADCC functions (Hessell
et al., 2007).
Despite the potential efﬁcacy of ADCC antibodies, little is known
about the speciﬁc HIV-1 epitopes that stimulate ADCC. To date, only
Env (Alsmadi et al., 1997) and Nef (Yamada et al., 2004)-speciﬁc ADCC
epitopes have been well characterized in HIV-1 infected subjects.
Most ADCC responses described in the literature are to the HIV-1
envelope protein (Env). Env is highly variable across HIV strains and
can readilymutate to escape NAb and CTL responses. Recent data from
our group shows ADCC responses to Env epitopes also force immune
escape (Chung et al., 2010). Ideal ADCC epitopes expressed by HIV
vaccines would be to conserve internal proteins.
Fig. 1. Flowchart of Pol-speciﬁc ADCC studies. 83 Subjects were initially tested for Pol-
speciﬁc ADCC responses, 32 showed a positive Pol response. Further mapping of these
32 subjects was then undertaken.
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the inefﬁcient and complex nature of the historical assays for
assessing ADCC responses. Typical killing-based ADCC assays measure
responses to large proteins and are not suited to mapping ADCC
responses. A novel ICS (intracellular cytokine staining) ADCC method
has recently been developed in our lab that allows the ﬁnemapping of
linear ADCC epitopes (Stratov et al., 2008). This assay measures NK
cell activation in response to ADCC antibodies targeting linear
epitopes within overlapping peptide sets. Although this is not a
“cytotoxicity” based assay, analysis of CD107a (a marker of cytotoxic
granule release) provides a surrogate of cytotoxicity and correlates
with a standard killing based ADCC assay (Chung et al., 2009).
Compared to existing killing based ADCC assays, no artiﬁcial cell line is
required, and either the patient's NK cells or healthy donor NK cells
used as the effector cells can be tested for ADCC activity alongwith the
assessment of NK cytokine production, chemokine production and
loss of perforin or granzymes (Chung et al., 2009). The ability to map
linear ADCC epitopes from within large pools of overlapping peptides
permits the identiﬁcation of the particular ADCC antibody.
Two of the most conserved HIV proteins are the Gag and Pol
proteins. Gag encodes capsid protein and Pol encodes for the
replication enzymes including Protease (PR), Integrase (IN) and
Reverse Transcriptase (RT). CTL responses that target Gag and Pol are
often highly effective and escape mutations often result in large
reductions in viral replicative capacity (large “ﬁtness cost”) (Hue et
al., 2009) (Clavel et al., 2000). Similarly, drug resistance mutations
within Pol proteins frequently result in ﬁtness costs (Rangel et al.,
2009). ADCC epitopes within these Gag and Pol proteins could be
valuable vaccine targets.
We prospectively studied ADCC responses to linear Gag and Pol
peptides in a cohort of 83 HIV-infected subjects using our ICS-based
ADCC assay. We found that Pol was commonly targeted by ADCC
responses in these chronically infected subjects but Pol-speciﬁc ADCC
responses did not correlate with delayed HIV progression.
Results
Pol is a target for ADCC responses
Envelope is the most well recognised ADCC target (Ahmad and
Menezes, 1996; Alsmadi and Tilley, 1998; Baum et al., 1996), but
ADCC responses to other more conserved HIV proteins such as Pol
proteins could help mediate control of viremia. We studied ADCC
responses to Pol peptide pools Pol 1 (Pol 1–124) and/or Pol 2 (125–
249) using our novel ADCC-ICS assay (Fig. 1). Subject responses
were mapped by gating on the lymphocyte population analysing the
expression of IFNγ and CD107a from CD56+ and CD2+ CD3− NK
cells (Fig. 2A). Thirty-two (39%) subjects of the eighty-three
assessed showed NK cells activated by one of the Pol overlapping
peptide pools (Fig. 1). Similarly to our previous studies on ADCC
responses to other HIV antigens (Chung et al., 2009), we found that
Pol peptides were required to be present on presenting cells. The
activation of NK cells was not diminished even if free peptides were
washed out prior to adding serum. The proportion of IFNγ
expressing NK cells in response to Pol peptides was 0.24% when
added directly to donor whole blood and serum, and 0.42% when
peptides were ﬁrst added to whole blood for 1 h then washed twice
before adding serum.
Wealsomeasured responses toGag andEnvpeptides andcompared
how frequent and robust ADCC responses to Pol were in comparison to
Env and Gag. Comparing Pol to Env and Gag we found 11 subjects had
CD3− CD2+ cells expressing IFNγ to Pol 1 (Mean±SE=0.30±0.05),
and 14 subjects showed responses to Pol 2 (Mean±SE=0.30±0.08),
34 responded to Env (Mean±SE=1.165±0.19) and only 3 to Gag
(Mean±SE=0.06±0.05) (Fig. 3A). As compared to CD3− CD2+
IFNγ+ expressing cells, CD3− CD2+ CD107a+ cells responded asfollows: 23 responses to Pol 1(Mean±SE=0.63±0.11) and 17
responses to Pol 2 (Mean±SE=0.29±0.09), 48 responded to Env
(Mean±SE=2.32±0.40) and 11 to Gag (Mean±SE=0.23±0.08)
(Fig. 3B).
Signiﬁcant ADCC responses to overlapping peptides of Pol 1 or Pol
2 were detected in a number of subjects (Fig. 3). The use of
overlapping peptide pools as antigens allows the mapping of
responses to smaller sets of peptides. We mapped responses to
smaller pools of Pol consisting of 19–21 Pol peptides per pool. Nine
subjects from the 32 Pol responders were mapped to at least one pool
of Pol peptides. We were further able to ﬁne map responses from 2
subjects to single Pol peptides (Fig. 2B). Subject 29 showed ADCC
responses to Pol pool 231–249, which was then mapped to Pol
peptides 233 (Fig. 2B).
Correlation of Pol speciﬁc ADCC responses with HIV progression
We detected Pol-speciﬁc ADCC responses in just under half of the
ART naïve, HIV positive subjects. We next asked whether Pol-speciﬁc
ADCC responses correlated with markers of HIV disease progression.
Pol-speciﬁc ADCC responses, as measured by NK cells expressing IFNγ
and CD107a in response to Pol peptides, were correlated to viral loads
(Fig. 4A) and CD4 T cell counts were assessed (Fig. 4B). No correlation
was evident between the subject's baseline viral load or CD4 T cell
count and ADCC response to Pol using the ADCC ICS assay, either by
IFNγ or CD107a expression analysis. We followed the subjects for a
mean of 3 years (2006–2010) after enrolment, during which time
they had regular CD4 T cell counts. The unpaired t test was used to
assess the relationship between the loss of CD4 T cell (CD4 count
slope) over time and Pol-speciﬁc ADCC responses (Fig. 4C). The
decline in CD4 T cell count over time did not correlate with the
presence of ADCC responses to Pol.
During follow up, the HIV infection of 45 subjects progressed such
that ART was initiated. The effects of ART on subjects with a response
to Pol were also calculated (Fig. 4D). Of the subjects, who progressed
to require ART, 45% were Pol responders and 31% of ART naïve
Fig. 2. Intracellular cytokine staining ADCC assay andmapping process. A.Gating strategy: lymphocytes from all cells identiﬁed and isolated CD3− cells to allow assessment of CD2+
and CD56+ NK cells expressing IFNγ. B. Subject response to Pol, Pol pool 1–124 and 125–249, mapped to Pol pool 231–249 and ﬁne mapped to Pol peptide Pol 233. Responses for
DMSO, Rev, Pol pool 126–146, and Pol 232 are included as irrelevant peptides or pools indicating negative ADCC responses.
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Pol-speciﬁc ADCC responses did not illustrate a signiﬁcant correlation
with progressive HIV disease.ADCC Pol-speciﬁc responses decline over time
Interestingly a number of subjects with initial responses to Pol and
Pol pools (Table 1) were unable to be ﬁne mapped to individual Pol
peptides at subsequent blood samples (Fig. 5). For example subject 2
had a Pol response of approximately 1% in 2006–2008, which was
mapped to Pol pools 168–188 (1.33%) and 210–230 (0.66%). (Table 1.)
However we were unable to later ﬁne map these responses to the
individual Pol peptides, since the ADCC response to Pol declined to
b0.1% in 2009–2010. This decline in Pol response over the years was
evident in most of the subjects (Fig. 5). Inability to ﬁne map some
subjects to speciﬁc Pol peptides may be explained by this decline in
response.Discussion
Until HIV-speciﬁc broadly neutralizing antibodies to envelope can
be reliably induced, it will be important to identify functional
immune responses to conserved HIV proteins, which can effectively
be induced by vaccination. Although some Gag-speciﬁc CD8+ CTLs
are associated with reduced HIV viral loads, only a subset of
individuals have the HLA class I alleles that can present the most
effective CTL responses. Effector antibody responses such as ADCC
that recognise conserved internal proteins, such as Gag and Pol, is a
potential method of targeting more broadly acting useful immune
responses.
This is the ﬁrst study to investigate in detail ADCC immune
responses to HIV-1 Pol and Gag proteins. We employed a recently
described ICS assay that assessed NK cell activation in response to
overlapping HIV peptides and ADCC antibodies in plasma (Chung et
al., 2009; Stratov et al., 2008). This assay measures both NK cell IFNγ
expression and CD107a expression (a degranulation marker), as
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Fig. 3. Env, Gag and Pol speciﬁc ADCC responses. Initial ADCC responses to Pol were
identiﬁed when ADCC responses were mapped for HIV proteins (Env, Gag and Pol).
Signiﬁcant ADCC responses for Env were ascertained as well as for Pol 1 and or Pol 2 by
a number of subjects.
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on antibodies that trigger NK cell activation. We studied a cohort of 83
HIV+ subjects not on ART and found 32 subjects with ADCC responses
to linear Pol peptides, although only 11 subjects targeted the Gag
protein (including those that expressed either IFNγ or CD107a or
both). Bymapping ADCC responses to smaller pools of Pol peptideswe
found that Pol proteins were broadly targeted by ADCC responses. The
majority of the higher responses N0.5% was to pools 126–249, which
correlates with the 5′ end of the Pol protein. This region expresses RT
and IN proteins. Targeting the RT and IN sections of Pol may prove
useful targets for a vaccine that elicits ADCC antibodies to induce
signiﬁcant ADCC immune responses against HIV infection. However,
we found no correlation between Pol-speciﬁc ADCC responses and
several markers of HIV progression in the cohort, including loss of CD4
T cells over time and the requirement for anti-retroviral therapy.
Interestingly, Pol-speciﬁc ADCC responses declined during the follow-
up of this cohort.
ADCC responses to HIV are induced early during HIV infection and
several studies have shown ADCC responses to Env proteins correlate
with slower HIV progression (Ahmad et al., 2001; Alsmadi and Tilley,
1998; Baum et al., 1996; Chung et al., 2008; Tyler et al., 1990). Env
readily mutates to escape other immune responses without signiﬁ-
cant loss in replicative capacity (i.e. minimal “ﬁtness cost”) and is
likely to mutate to avoid ADCC responses (Richman et al., 2003). Pol
speciﬁc CTL epitopes can also mutate to escape immune pressure
although there may be bigger ﬁtness costs associated with escape
from Pol speciﬁc ADCC responses in comparison to Env-speciﬁc
responses. Similarly, Pol-speciﬁc mutations induced during the
development of antiretroviral drug resistance also frequently result
in signiﬁcant ﬁtness costs (Sun et al., 2009). Mapping of multiple Pol-
speciﬁc responses to speciﬁc epitopes allows the assessment ofimmune escape mutations within the Pol-speciﬁc ADCC epitope.
Evidence of escape would suggest some immune pressure is being
applied by Pol-speciﬁc ADCC responses and explain in part the lack of
correlation with disease progression observed. It is important to note
that our results are restricted to analysing linear rather than
conformational Pol-speciﬁc ADCC responses. Conformational Pol-
speciﬁc ADCC epitopes could bemore effective at slowing HIV disease.
Future studies could evaluate Pol-speciﬁc ADCC responses using
puriﬁed whole Pol proteins.
ADCC responses generally target viral proteins expressed on the
surface of infected cells (Ahmad and Menezes, 1996). Since Pol is
composed of several enzymes which act intracellularly, with very
little of the protein expressed within virions, it is not clear how Pol
proteins would be recognised by ADCC antibodies. Alternatively, the
ADCC recognition of Pol proteins may primarily be induced by
recognition of viral debris form lysed infected cells — in this scenario
Pol would not be expected to delay disease progression as we
observed. Precisely which cells would present Pol peptides is
unclear. Phagocytic cells such as neutrophils and macrophages
may scavenge Pol antigens and present them to ADCC antibodies.
Future studies of puriﬁed Pol-speciﬁc ADCC antibodies could assess
whether HIV replication is inhibited in vitro using the antibody-
dependent cellular viral inhibition assay described by Forthal et al.,
(2006).
Interestingly, we observed a general decline in linear Pol-speciﬁc
ADCC responses during follow up of the cohort. This restricted our
ability to map responses to minimal epitopes. Others have also
observed decline in HIV-speciﬁc ADCC responses over time (Baum et
al., 1996). Decreases in numbers and function of circulating NK cells is
likely to contribute in part to this decrease in ADCC activity during HIV
infection (Fauci et al., 2005; Kottilil et al., 2003; Mavilio et al., 2005,
2006). A decrease in the function of ADCC effector cells over time
would restrict the ability of ADCC responses to slow HIV disease
progression as we observed. In addition, a decline in all HIV-speciﬁc
antibodies is commonly observed in late stage HIV disease (Popovic et
al., 1984). However, wemight expect that ADCC responses induced by
vaccination (prior to HIV infection) would be fully functional and
could be capable of contributing to prevention of HIV infection. A
modest reduction in numbers of new infectionswas recently observed
in the Thai RV 144 HIV vaccine efﬁcacy trial (Rerks-Ngarm et al.,
2009). The vaccine regimen infrequently induced CTL responses and
induces only narrowly directed Nab responses but does induce robust
ADCC responses (Karnasuta et al., 2005). Several groups have
speculated that ADCC responses may be in part responsible for the
protection observed by SIV vaccine regimens in macaques (Florese et
al., 2006; Gomez-Roman et al., 2005).
In summary, we found Pol is a signiﬁcant target for ADCC
responses in HIV-1 infected subjects but that Pol-speciﬁc ADCC
responses declined over time and did not correlate with slower
progression of HIV infection. To further probe these ﬁndings, future
studies are needed to resolve both the mechanisms of induction and
presentation of Pol-speciﬁc ADCC responses and whether such
responses force immune escape over time.
Materials and methods
Study subjects
To study Pol-speciﬁc ADCC responses in HIV-infected adults we
recruited 83 HIV positive individuals not on antiretroviral therapy
prospectively to donate blood samples in 2006 to 2007 with a
follow-up period of 2 years (range 1–3 years). Subjects were
recruited through the Melbourne Sexual Health Centre and the
Alfred Hospital, Melbourne, Australia. All subjects provided in-
formed consent. Blood samples were analysed at the start of follow-
up and 2 years after recruitment. The subjects provided 9–18 ml of
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Fig. 4. Correlation of Pol-speciﬁc ADCC responses with HIV progression. Correlation of Pol responses, NK cells expressing IFNγ and CD107a to A. viral loads and B. CD4 T cell at
recruitment to the study were undertaken. No correlation was evident with all parameters analysed against Pol-speciﬁc ADCC responses. C. The unpaired t test was used to assess the
relationship between the loss of CD4 T cell (CD4 count slope) over time and whether or not subjects had a detectable Pol-speciﬁc ADCC response. The decline in CD4 T cell count over
time did not correlate with the presence of an ADCC response to Pol. D. The effects of ART on subjects with a response to Pol were also calculated. Of the subjects, who progressed to
require ART, 45% were Pol responders and 31% of ART naïve subjects were also responding to Pol (P=0.52).
114 G. Isitman et al. / Virology 412 (2011) 110–116Na-heparin anticoagulated blood for analysis using the ADCC-ICS
assay. During the follow up period 45 of the 83 subjects started
antiretroviral therapy for HIV progression at the discretion of thetreating physician and were censored for follow up at that time.
The relevant human research ethics committee approved all
studies.
Table 1
Mapping of Pol-speciﬁc ADCC responses to pools of 20 overlapping peptides.
Pol peptide pools
Subject 1–20 21–41 42–62 63–83 84–104 105–125 126–146 147–167 168–188 189–209 210–230 231–249
2 1.33⁎ 0.66⁎
11 0.68# 0.63+
29 0.7+ 0.8^ 1.31+ 1.71+
46 0.37+ 0.35+
53 2.45^ 0.92^ 0.65^ 1.202^ 0.862^ 0.621^ 1.102^ 0.872^ 1.042^ 0.752^ 0.658^
62 0.7^
65 0.445^
67 0.59^ 0.43⁎ 0.57# 1.32^
80 0.383^ 0.368^ 0.362^ 0.51^
Maximum response for each pool shown based on gating *CD56+ CD107a+; +CD56+ IFNγ+; #CD2+ IFNγ+; ^CD2+ CD107a+.
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ADCC responses were detected using 249 Consensus B subtype Pol
peptides (15-mers, overlapping by 11 amino acids, solubilized in pure
dimethyl sulfoxide (DMSO), divided into two pools (Pol 1–124, Pol
125–249)), spanning all HIV-1 Pol proteins using a consensus subtype
B (kindly supplied by the NIH AIDS Reagent Repository). Pol-speciﬁc
responses were further mapped by creating sub-pools of 20 or 21
individual peptides and further mapped to single Pol 15mer peptides.
Fine mapping of Pol-speciﬁc ADCC responses was conducted
approximately two years after enrolment of subjects in the study.
Pol-speciﬁc responses were compared to responses to a pool of 212
consensus B subtype Env and 123 Gag 15mer overlapping peptide
pools (NIH AIDS Reagent Repository).
Analysis of Pol-speciﬁc ADCC responses
The NK cell activation ADCC ICS assay was performed on all
subjects using fresh sodium-heparinized whole blood to measure
responses to Pol 1 and Pol 2 peptide pools. To map Pol-speciﬁc ADCC
responses we studied stored plasma mixed with fresh healthy donor
whole blood as previously described (Stratov et al., 2008). Samples
were incubated at 37 °C for 5 h with peptides at a ﬁnal concentration
of 1 μg/ml of peptide in the presence of Brefeldin A (0.25 mg/ml) and
Monensin (5 mg/ml) (Sigma). Negative (DMSO alone) and positive
control (combined SEB (Staphylococcus enterotoxin B) Sigma) wells
were included. Cells were surface stained with antibodies obtained
from BD Biosciences CD2-FITC (ﬂuorescein isothiocyanate), CD3-PE
(phycoerythrin), CD56-PerCP (peridinin chlorophyll protein) and
CD107a-APC (allophycocyanin). Lysis was performed on the stained2 3 4 7 9 11 15 29 31 40 42 45 46 53 54 56 59 62 65 67 68 70 72 75 78 81 83
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Fig. 5. Changes in Pol-speciﬁc ADCC responses over time. A decline in Pol-speciﬁc ADCC
responses over time occurred in the majority of subjects.cells and permeabilized, and stained intracellularly with IFN- AF700
(AlexaFlour700). Data was collected using the FACS Canto analyser
and data analysis was performed on FlowJo 9.0.2 software for CD56+
and CD2+ NK cells expressing IFNγ and CD107a within a CD3−
lymphocyte gate. A Pol speciﬁc response was deﬁned into two parts
with a Pol response to Pol 1 (Pol 1-124) as N0.65% and to Pol 2 (Pol
125-249) as N0.32%. This criteria was based on greater than 2 standard
deviations above the mean response to Pol 1-124 and Pol 125-249 in
HIV-1 negative subjects (n=12).
Statistical analysis
All statistical analyses were performed using Prism 4.0c (Graph-
Pad). Analysis of correlation between CD4 counts and viral load with
percent IFNγ and CD107a expression of NK cells to Pol peptides were
evaluated using the linear regression test (Fig. 4A and B). Calculations
of CD4 count slope (Fig. 4C) were determined in Excel (Microsoft)
before assessing the signiﬁcance of the results using the unpaired
t test and the Fisher's exact test for Fig. 4D.
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